164 related articles for article (PubMed ID: 27309188)
1. Follow-up of patients with ECL cell-derived tumours.
Sagatun L; Fossmark R; Jianu CS; Qvigstad G; Nordrum IS; Mjønes P; Waldum HL
Scand J Gastroenterol; 2016 Nov; 51(11):1398-405. PubMed ID: 27309188
[TBL] [Abstract][Full Text] [Related]
2. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Fykse V; Waldum HL
Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
[TBL] [Abstract][Full Text] [Related]
3. Treatment of ECL cell carcinoids with octreotide LAR.
Fykse V; Sandvik AK; Qvigstad G; Falkmer SE; Syversen U; Waldum HL
Scand J Gastroenterol; 2004 Jul; 39(7):621-8. PubMed ID: 15370681
[TBL] [Abstract][Full Text] [Related]
4. Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis.
Massironi S; Zilli A; Fanetti I; Ciafardini C; Conte D; Peracchi M
Dig Liver Dis; 2015 Nov; 47(11):978-83. PubMed ID: 26321479
[TBL] [Abstract][Full Text] [Related]
5. Presentation, treatment, and outcome of type 1 gastric carcinoid tumors.
Dakin GF; Warner RR; Pomp A; Salky B; Inabnet WB
J Surg Oncol; 2006 Apr; 93(5):368-72. PubMed ID: 16550587
[TBL] [Abstract][Full Text] [Related]
6. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A.
Fossmark R; Sørdal Ø; Jianu CS; Qvigstad G; Nordrum IS; Boyce M; Waldum HL
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1067-75. PubMed ID: 23072686
[TBL] [Abstract][Full Text] [Related]
7. One-year follow-up study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release.
Fykse V; Sandvik AK; Waldum HL
Scand J Gastroenterol; 2005 Nov; 40(11):1269-74. PubMed ID: 16334435
[TBL] [Abstract][Full Text] [Related]
8. Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours.
Grozinsky-Glasberg S; Kaltsas G; Gur C; Gal E; Thomas D; Fichman S; Alexandraki K; Barak D; Glaser B; Shimon I; Gross DJ
Eur J Endocrinol; 2008 Oct; 159(4):475-82. PubMed ID: 18662970
[TBL] [Abstract][Full Text] [Related]
9. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.
Moore AR; Boyce M; Steele IA; Campbell F; Varro A; Pritchard DM
PLoS One; 2013; 8(10):e76462. PubMed ID: 24098507
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study.
Thomas D; Tsolakis AV; Grozinsky-Glasberg S; Fraenkel M; Alexandraki K; Sougioultzis S; Gross DJ; Kaltsas G
Eur J Endocrinol; 2013 Feb; 168(2):185-93. PubMed ID: 23132699
[TBL] [Abstract][Full Text] [Related]
11. Spontaneous enterochromaffin-like cell carcinomas in cotton rats (Sigmodon hispidus) are prevented by a somatostatin analogue.
Fossmark R; Martinsen TC; Torp SH; Kawase S; Sandvik AK; Waldum HL
Endocr Relat Cancer; 2004 Mar; 11(1):149-60. PubMed ID: 15027892
[TBL] [Abstract][Full Text] [Related]
12. The gastric mucosa 25 years after proximal gastric vagotomy.
Sagatun L; Jianu CS; Fossmark R; Mårvik R; Nordrum IS; Waldum HL
Scand J Gastroenterol; 2014 Oct; 49(10):1173-80. PubMed ID: 25157752
[TBL] [Abstract][Full Text] [Related]
13. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.
Khuroo MS; Khuroo MS; Khuroo NS
J Gastroenterol Hepatol; 2010 Mar; 25(3):548-54. PubMed ID: 20074162
[TBL] [Abstract][Full Text] [Related]
14. [Effective treatment of a hormonally inactive carcinoid tumour with somatostatin analogues: application of serum chromogranin-A for clinical follow-up].
Igaz P; Rácz K; Tulassay Z
Orv Hetil; 2007 Dec; 148(49):2343-6. PubMed ID: 18048114
[TBL] [Abstract][Full Text] [Related]
15. Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids.
Sullivan I; Le Teuff G; Guigay J; Caramella C; Berdelou A; Leboulleux S; Déandréis D; Hadoux J; Ducreux M; Duvillard P; Adam J; Scoazec JY; Baudin E; Planchard D
Eur J Cancer; 2017 Apr; 75():259-267. PubMed ID: 28242503
[TBL] [Abstract][Full Text] [Related]
16. A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors.
Berna MJ; Annibale B; Marignani M; Luong TV; Corleto V; Pace A; Ito T; Liewehr D; Venzon DJ; Delle Fave G; Bordi C; Jensen RT
J Clin Endocrinol Metab; 2008 May; 93(5):1582-91. PubMed ID: 18270260
[TBL] [Abstract][Full Text] [Related]
17. Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs.
Campana D; Nori F; Pezzilli R; Piscitelli L; Santini D; Brocchi E; Corinaldesi R; Tomassetti P
Endocr Relat Cancer; 2008 Mar; 15(1):337-42. PubMed ID: 18310299
[TBL] [Abstract][Full Text] [Related]
18. Metastatic type 1 gastric carcinoid: a real threat or just a myth?
Grozinsky-Glasberg S; Thomas D; Strosberg JR; Pape UF; Felder S; Tsolakis AV; Alexandraki KI; Fraenkel M; Saiegh L; Reissman P; Kaltsas G; Gross DJ
World J Gastroenterol; 2013 Dec; 19(46):8687-95. PubMed ID: 24379587
[TBL] [Abstract][Full Text] [Related]
19. Management and clinical outcomes of type I gastric carcinoid patients: retrospective, multicenter study in Japan.
Sato Y; Imamura H; Kaizaki Y; Koizumi W; Ishido K; Kurahara K; Suzuki H; Fujisaki J; Hirakawa K; Hosokawa O; Ito M; Kaminishi M; Furuta T; Chiba T; Haruma K
Dig Endosc; 2014 May; 26(3):377-84. PubMed ID: 24188531
[TBL] [Abstract][Full Text] [Related]
20. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
